Madrigal Pharmaceuticals
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$14.0M
Doctors Paid
8,952
Transactions
20,807
2024 Total
$14.0M
Payment Breakdown by Category
Research$9.5M (67.9%)
Food & Beverage$774,118 (5.5%)
Travel$367,225 (2.6%)
Consulting$41,214 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.5M | 1,201 | 67.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.0M | 1,071 | 21.6% |
| Food and Beverage | $774,118 | 17,111 | 5.5% |
| Travel and Lodging | $367,225 | 1,140 | 2.6% |
| Honoraria | $238,078 | 68 | 1.7% |
| Consulting Fee | $41,214 | 66 | 0.3% |
| Space rental or facility fees (teaching hospital only) | $40,750 | 7 | 0.3% |
| Education | $5,999 | 141 | 0.0% |
| Grant | $5,000 | 2 | 0.0% |
Payments by Type
Research
$9.5M
1,201 transactions
General
$4.5M
19,606 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | $5.1M | 0 | 592 |
| A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | $2.9M | 0 | 442 |
| A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | $1.5M | 0 | 154 |
| A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1) | $11,773 | 0 | 5 |
| A Phase 1, Multi-center, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function | $8,201 | 0 | 1 |
| A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation | $592.42 | 0 | 7 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Santiago Munoz, Md, MD | Transplant Hepatology | Toms River, NJ | $108,336 | $0 |
| Dr. Zahid Vahora, Md, MD | Transplant Hepatology | Washington, DC | $86,246 | $0 |
| Naim Alkhouri, Md, MD | Internal Medicine | Westlake, OH | $80,264 | $0 |
| Dr. Julio Gutierrez, Md, MD | Internal Medicine | Los Angeles, CA | $53,665 | $0 |
| Dr. Nadege Gunn, M.d, M.D | Gastroenterology | Waco, TX | $53,155 | $0 |
| Dr. Mazen Noureddin, M.d, M.D | Gastroenterology | Houston, TX | $51,179 | $0 |
| Parvez Mantry, Md, MD | Hepatology | Dallas, TX | $49,925 | $0 |
| Dr. Anthony Martinez, M.d, M.D | Internal Medicine | Buffalo, NY | $48,799 | $0 |
| Sonja Olsen, M.d, M.D | Internal Medicine | West Palm Beach, FL | $48,472 | $0 |
| Phillip Henderson, D.o, D.O | Internal Medicine | Mobile, AL | $43,551 | $0 |
| Lance Stein, Md, MD | Transplant Hepatology | Atlanta, GA | $42,664 | $0 |
| Apurva Modi, M.d, M.D | Hepatology | Fort Worth, TX | $41,885 | $0 |
| Dilip Moonka, M.d, M.D | Gastroenterology | Detroit, MI | $38,730 | $0 |
| Dr. Anurag Maheshwari, M.d, M.D | Hepatology | Baltimore, MD | $37,686 | $0 |
| Robert Gish, M.d, M.D | Gastroenterology | Folsom, CA | $37,106 | $0 |
| Dr. Adnan Muhammad, M.d, M.D | Transplant Hepatology | Tampa, FL | $36,771 | $0 |
| Joykumar Patel, M.d, M.D | Hepatology | Oklahoma City, OK | $34,837 | $0 |
| Dr. Justin Reynolds, Md, MD | Gastroenterology | Peoria, AZ | $34,576 | $0 |
| Dr. Barry Migicovsky, M.d, M.D | Gastroenterology | Boulder, CO | $34,450 | $0 |
| Naoky Tsai, Md, MD | Gastroenterology | Kailua, HI | $32,099 | $0 |
| Dr. Manuel Rodriguez, M.d, M.D | Gastroenterology | Bradenton, FL | $31,834 | $0 |
| Kamran Qureshi, Md, MD | Gastroenterology | Lake St Louis, MO | $30,992 | $0 |
| Dr. Vinod Rustgi, Md, MD | Gastroenterology | New Brunswick, NJ | $30,273 | $0 |
| Ana Corregidor, Md, MD | Gastroenterology | Jacksonville, FL | $29,789 | $0 |
| Ari Bunim, Md, MD | Internal Medicine | Flushing, NY | $29,658 | $0 |
Ad
Top Products
- REZDIFFRA $4.1M
- RESMETIROM $1.7M
Associated Products (2)
- REZDIFFRA $4.1M
- RESMETIROM $1.7M
Payment Categories
- Food & Beverage $774,118
- Consulting $41,214
- Travel & Lodging $367,225
- Research $9.5M
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals has made $14.0M in payments to 8,952 healthcare providers, recorded across 20,807 transactions in the CMS Open Payments database. In 2024, the company paid $14.0M. The top product by payment volume is REZDIFFRA ($4.1M).
Payments were distributed across 109 medical specialties. The top specialty by payment amount is Gastroenterology ($1.7M to 2,946 doctors).
Payment categories include: Food & Beverage ($774,118), Consulting ($41,214), Research ($9.5M), Travel & Lodging ($367,225).
Madrigal Pharmaceuticals is associated with 2 products in the CMS Open Payments database.